EL7.AI
StocksMedium•17 March 2026•
1 min read

Nuvation Bio to Present Pivotal IBTROZI Clinical Data at AACR 2026

Key Facts

1Nuvation Bio will present updated data from the TRUST-I and TRUST-II clinical studies at the AACR 2026 meeting.
2IBTROZI (taletrectinib) demonstrated a median Duration of Response (DOR) of 50 months in TKI-naïve patients.
3The data targets patients with advanced ROS1-positive non-small cell lung cancer (NSCLC).

Nuvation Bio Inc. (NYSE: NUVB) has announced it will present updated clinical data for its lead oncology candidate, IBTROZI (taletrectinib), at the AACR Annual Meeting 2026. The presentation will feature results from the pivotal TRUST-I and TRUST-II studies, focusing on patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). A key highlight includes a median Duration of Response (DOR) of 50 months for patients who had not previously received TKI inhibitors. These findings underscore the potential durability and efficacy of IBTROZI in treating specific lung cancer populations. The company aims to demonstrate the long-term clinical benefits of its therapeutic approach within the competitive oncology landscape. Investors are closely watching the upcoming data release as a significant milestone for the biotech firm's development pipeline.